Comparative analyses of erythroblast transformation specific-1 related gene expression before and after neoadjuvant bevacizumab therapy for newly diagnosed glioblastoma.

IF 1.1 Q4 ONCOLOGY International journal of clinical and experimental pathology Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI:10.62347/GQWP4029

Ai Iwauchi, Nei Fukasawa, Jun Takei, Miku Maeda, Kyoichi Tomoto, Akihiko Teshigawara, Yohei Yamamoto, Yasuharu Akasaki, Yuzuru Hasegawa, Yuichi Murayama, Keisuke Miyake, Masayuki Shimoda, Toshihide Tanaka

{"title":"Comparative analyses of erythroblast transformation specific-1 related gene expression before and after neoadjuvant bevacizumab therapy for newly diagnosed glioblastoma.","authors":"Ai Iwauchi, Nei Fukasawa, Jun Takei, Miku Maeda, Kyoichi Tomoto, Akihiko Teshigawara, Yohei Yamamoto, Yasuharu Akasaki, Yuzuru Hasegawa, Yuichi Murayama, Keisuke Miyake, Masayuki Shimoda, Toshihide Tanaka","doi":"10.62347/GQWP4029","DOIUrl":null,"url":null,"abstract":"Objective: The aim of the present study was to investigate the expression of erythroblast transformation specific-1 related gene (ERG) in patients with glioblastoma (GB) before and after bevacizumab (Bev) therapy as a predictive and prognostic biomarker.Methods: The present study used 58 GB tissues from 29 patients in 3 settings. Sixteen tumors were removed after neoadjuvant Bev administration (neoBev) and 13 represented newly diagnosed GB without previous Bev treatment (naïve Bev). Another 29 specimens of recurrence were obtained from salvage surgery or autopsy.Results: Immunohistochemical analysis showed both vessel density (VD) and ERG score were decreased in neoBev compared with naïve Bev. VD and ERG score tended to be lower at recurrence than at initial surgery (P=0.0026 and P=0.1338, respectively). In the naïve Bev and neoBev cohorts, overall survival (OS) with high and low expressions of ERG was comparable (P=0.7516 and P=0.3862, respectively).Conclusion: High expression of ERG in GB with naïveBev was significantly reduced with Bev, but not changed in refractoriness. Stratification of ERG expression levels might provide a useful predictive biomarker for GB treated with Bev.","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558313/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of clinical and experimental pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62347/GQWP4029","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The aim of the present study was to investigate the expression of erythroblast transformation specific-1 related gene (ERG) in patients with glioblastoma (GB) before and after bevacizumab (Bev) therapy as a predictive and prognostic biomarker.

Methods: The present study used 58 GB tissues from 29 patients in 3 settings. Sixteen tumors were removed after neoadjuvant Bev administration (neoBev) and 13 represented newly diagnosed GB without previous Bev treatment (naïve Bev). Another 29 specimens of recurrence were obtained from salvage surgery or autopsy.

Results: Immunohistochemical analysis showed both vessel density (VD) and ERG score were decreased in neoBev compared with naïve Bev. VD and ERG score tended to be lower at recurrence than at initial surgery (P=0.0026 and P=0.1338, respectively). In the naïve Bev and neoBev cohorts, overall survival (OS) with high and low expressions of ERG was comparable (P=0.7516 and P=0.3862, respectively).

Conclusion: High expression of ERG in GB with naïveBev was significantly reduced with Bev, but not changed in refractoriness. Stratification of ERG expression levels might provide a useful predictive biomarker for GB treated with Bev.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

新诊断胶质母细胞瘤贝伐单抗新辅助治疗前后红细胞转化特异性-1相关基因表达的比较分析

研究目的本研究旨在探讨红细胞转化特异性-1相关基因（ERG）在胶质母细胞瘤（GB）患者贝伐单抗（Bev）治疗前后的表达情况，并将其作为预测和预后的生物标志物：本研究使用了3种情况下29名患者的58个胶质母细胞瘤组织。其中16例肿瘤是在新辅助贝伐单抗治疗（neoBev）后切除的，13例为新诊断的GB，之前未接受过贝伐单抗治疗（naïve Bev）。另外 29 例复发标本来自挽救手术或尸检：免疫组化分析显示，与新Bev相比，新Bev的血管密度（VD）和ERG评分均有所下降。复发时的血管密度和ERG评分往往低于初次手术时（分别为P=0.0026和P=0.1338）。在新Bev和neoBev队列中，ERG高表达和低表达的总生存期（OS）相当（分别为P=0.7516和P=0.3862）：结论：ERG的高表达在使用naïveBev的GB中明显减少，但在难治性方面没有变化。ERG表达水平的分层可为Bev治疗的GB提供有用的预测性生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International journal of clinical and experimental pathology ONCOLOGY-PATHOLOGY

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： The International Journal of Clinical and Experimental Pathology (IJCEP, ISSN 1936-2625) is a peer reviewed, open access online journal. It was founded in 2008 by an international group of academic pathologists and scientists who are devoted to the scientific exploration of human disease and the rapid dissemination of original data. Unlike most other open access online journals, IJCEP will keep all the traditional features of paper print that we are all familiar with, such as continuous volume and issue numbers, as well as continuous page numbers to keep our warm feelings towards an academic journal. Unlike most other open access online journals, IJCEP will keep all the traditional features of paper print that we are all familiar with, such as continuous volume and issue numbers, as well as continuous page numbers to keep our warm feelings towards an academic journal.